VSEE · XBRL financial data

VSee Health financial statements, every quarter

The same tables from 14 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (VSEE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Revenue	—	—	—	—	3,354	3,734*	3,321	1,055	—	year only	3,160	1,562
Revenue from contracts with customers	1,433	1,484*	1,621	1,712	3,354	3,859*	3,321	3,390	3,981	3,926*	3,160	1,562
Cost of revenue	—	year only	386	935	570	1,353*	1,462	1,802	1,907	2,092*	1,962	1,356
Cost of goods and services sold	478	—	—	487	941	—	—	—	—	—	—	—
Gross profit	954	—	1,235	1,225	2,413	—	1,860	1,588	2,073	—	1,198	206
General and administrative	285	190*	674	509	2,170	3,723*	2,032	2,173	2,917	2,915*	2,440	2,254
Total operating expenses	1,307	1,194*	1,131	2,408	59,479	6,370*	3,691	3,843	4,131	5,274*	4,172	2,903
Operating income (loss)	(518)	(926)*	(674)	(1,183)	(57,066)	(3,940)*	(1,831)	(2,255)	(2,058)	(3,439)*	(2,974)	(2,697)
Interest income	104	57*	18	—	—	—	—	—	—	—	—	—
Interest expense	36	28*	9	342	115	(380)*	9	241	756	1,085*	113	9
Other income (expense)	—	(40)*	0	0	(0)	1*	16	167	(0)	(136)*	0	0
Income tax expense (benefit)	(234)	2,429*	0	(2,241)	(550)	1,148*	14	4	0	50*	24	(18)
Net income (loss)	78	(2,861)*	(968)	(330)	(51,752)	(5,618)*	(3,959)	(2,613)	(290)	(7,850)*	(2,600)	(1,744)*
Earnings per share, basic‡ USD per share	0.01	(0.30)*	(0.11)	(0.06)	(3.43)	—	(0.24)	(0.16)	(0.02)	—	(0.05)	—
Earnings per share, diluted‡ USD per share	0.01	(0.30)*	(0.11)	(0.06)	(3.43)	—	(0.24)	(0.16)	(0.02)	—	(0.05)	—
Weighted average shares, basic‡ thousands of shares	10,458	9,639*	9,010	5,302	15,078	11,396*	16,312	16,423	16,549	—	47,903	53,658
Weighted average shares, diluted‡ thousands of shares	10,458	9,639*	9,010	5,302	15,078	11,396*	16,312	16,423	16,549	—	47,903	53,658

‡ Per-share figures and share counts are adjusted for the 2.5-for-1 stock split (June 2024); filings made before it reported them unadjusted.

Balance sheet

CSV

Fiscal quarters (VSEE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Cash and cash equivalents	1	2	1	1,106	2,327	326	410	292	473	5,266	1,346	454
Accounts receivable	—	603	—	2,514	2,613	1,716	1,851	1,617	2,578	2,521	2,671	2,231
Prepaid and other current assets	—	80	—	761	1,606	447	530	410	383	274	511	266
Total current assets	18	2	1	5,167	7,108	3,021	3,080	2,560	3,718	8,365	4,841	3,266
Property and equipment, net	—	4	—	883	795	680	598	506	419	333	265	113
Right-of-use asset	—	—	—	692	418	380	359	338	316	13	11	8
Goodwill	—	—	—	59,901	4,917	4,917	4,917	4,917	4,917	4,917	4,917	4,917
Total assets	8,138	1,371	1,387	78,988	25,030	19,992	19,396	18,210	18,707	22,413	19,016	16,734
Accounts payable	—	417	—	—	—	4,283	4,208	4,402	5,790	5,528	3,836	3,808
Accrued liabilities	32	—	—	—	—	—	—	—	—	—	—	—
Current portion of long-term debt	—	220	—	928	439	434	1,091	1,460	1,945	1,242	524	335
Total current liabilities	5,022	7,984	8,969	22,880	19,206	19,010	21,983	23,058	23,422	16,245	11,795	8,096
Long-term debt	—	—	—	594	594	594	594	594	589	594	782	782
Lease liability, non-current	—	—	—	472	289	269	249	227	204	3	0	0
Total liabilities	9,392	12,354	13,339	24,177	20,271	20,011	22,893	23,946	24,283	16,961	12,695	9,142
Accumulated deficit	(9,772)	(12,816)	(13,784)	(9,773)	(61,525)	(67,704)	(71,663)	(74,277)	(74,566)	(82,417)	(85,017)	(84,170)
Total stockholders' equity	(9,149)	(12,266)	(13,234)	—	—	(18)	(3,497)	(5,736)	(5,575)	—	—	—
Total liabilities and equity	8,138	1,371	1,387	78,988	25,030	19,992	19,396	18,210	18,707	22,413	19,016	16,734
Common shares outstanding (cover page)‡ thousands of shares	8,960	9,010	9,010	14,807	15,362	16,423	17,023	17,023	31,348	47,299	48,599	56,680

‡ Per-share figures and share counts are adjusted for the 2.5-for-1 stock split (June 2024); filings made before it reported them unadjusted.

Cash flows

CSV

Fiscal quarters (VSEE's year ends in late December)

In thousands of dollars	Q3 FY23Sep 30, 2023	Q4 FY23Dec 31, 2023	Q1 FY24Mar 31, 2024	Q2 FY24Jun 30, 2024	Q3 FY24Sep 30, 2024	Q4 FY24Dec 31, 2024	Q1 FY25Mar 31, 2025	Q2 FY25Jun 30, 2025	Q3 FY25Sep 30, 2025	Q4 FY25Dec 31, 2025	Q1 FY26Mar 31, 2026	Q2 FY26Jun 30, 2026
Net income (loss)	78	(2,861)*	(968)	(330)	(51,752)	(5,618)*	(3,959)	(2,613)	(290)	(7,850)*	(2,600)	(1,744)*
Net cash from operating activities	(50)*	(321)*	(335)	(2,259)*	(221)*	(2,974)*	(440)	(325)*	(755)*	(1,926)*	(2,452)	(1,174)*
Purchases of property and equipment	0*	2*	9	37*	5*	5*	12	4*	7*	7*	27	73*
Net cash from investing activities	0*	6,808*	(9)	(8)*	(5)*	(5)*	(12)	(4)*	(7)*	(7)*	(127)	(2)*
Proceeds from issuing common stock	—	—	0	0*	0*	0*	91	0*	451*	959*	0	0*
Share repurchases	—	year only	—	—	—	5*	0	0*	0*	0*	50	0*
Net cash from financing activities	20*	(6,485)*	334	3,264*	1,447*	978*	536	210*	943*	6,727*	(1,341)	499*
Net change in cash	(30)*	1*	(1)	988*	1,221*	(2,001)*	84	(119)*	181*	4,794*	(3,920)	(677)*

Compare with peers

SIC 8000 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8000 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Vsee Health	454	1,562	(1,174)*	56.7M	0.4 quarters	Q2 FY26 10-QJun 30, 2026
P3 Health Partners	21,272	386,381	(61,914)*	not reported	0.3 quarters	Q2 FY26 10-QJun 30, 2026
Longduoduo	1,589	631*	275*	30.0M	—	Q4 FY26 10-KJun 30, 2026
Agape ATP	45	109	(110)*	1.0M	0.4 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.